Subscribe to RSS
DOI: 10.1055/a-0765-9523
Characterization of Casearin X Metabolism by Rat and Human Liver Microsomes
Publication History
received 04 July 2018
revised 05 October 2018
accepted 16 October 2018
Publication Date:
29 October 2018 (online)
Abstract
Casearin X (CAS X) is the major clerodane diterpene isolated from the leaves of Casearia sylvestris and has been extensively studied due to its powerful cytotoxic activity at low concentrations. Promising results for in vivo antitumor action have also been described when CAS X was administered intraperitoneally in mice. Conversely, loss of activity was observed when orally administered. Since the advancement of natural products as drug candidates requires satisfactory bioavailability for their pharmacological effect, this work aimed to characterize the CAS X metabolism by employing an in vitro microsomal model for the prediction of preclinical pharmacokinetic data. Rat and human liver microsomes were used to assess species differences. A high-performance liquid chromatography with diode-array detection (HPLC-DAD) method for the quantification of CAS X in microsomes was developed and validated according to European Medicines Agency guidelines. CAS X was demonstrated to be a substrate for carboxylesterases via hydrolysis reaction, with a Michaelis-Menten kinetic profile. The enzyme kinetic parameters were determined, and the intrinsic clearance was 1.7-fold higher in humans than in rats. The hepatic clearance was estimated by in vitro-in vivo extrapolation, resulting in more than 90% of the hepatic blood flow for both species. A qualitative study was also carried out for the metabolite identification by mass spectrometry and indicated the formation of the inactive metabolite CAS X dialdehyde. These findings demonstrate that CAS X is susceptible to first-pass metabolism and is a substrate for specific carboxylesterases expressed in liver, which may contribute to a reduction in antitumor activity when administered by the oral route.
Key words
in vitro metabolism - enzyme kinetics - natural product - casearin X - Casearia sylvestris - SalicaceaeSupporting Information
- Supporting Information
Chromatograms for the analysis of the selectivity of the method, validation parameters of the CAS X quantification method by HPLC, mass spectra of the CAS X metabolite and its fragmentation obtained by sequential mass spectrometry (LC-ESI-IT-MS/MS) and high-resolution mass spectrometry (MS-ESI-Q-TOF) are available as Supporting Information.
-
References
- 1 Carvalho PER. Espécies arbóreas brasileiras. Brasilia: EMBRAPA; 2006: 627
- 2 Xia L, Guo Q, Tu P, Chai X. The genus Casearia: a phytochemical and pharmacological overview. Phytochem Rev 2014; 14: 99-135
- 3 Hoehne FC. Plantas e Substâncias vegetais tóxicas e medicinais. Sao Paulo: Graphicars; 1939: 196-199
- 4 Correa MP. Dicionário das Plantas Úteis do Brasil e das Espécies cultivadas. Brasilia: EMBRAPA; 1975: 514-516
- 5 Junges MJ, Schenkel EP, Simões CMO. Flavonóides da Casearia sylvestris Sw. (erva de bugre). Porto Alegre: Caderno de Farmácia; 1985: 95-101
- 6 Basile AC, Sertiè JA, Panizza S, Oshiro TT, Azzolini C. A pharmacological assay of Casearia sylvestris: preventive antiulcer activity and toxicity of the leaf crude extract. J Ethnopharmacol 1990; 30: 185-197
- 7 Sertiè JA, Carvalho JC, Panizza S. Antiulcer activity of crude extract from the leaves of Casearia sylvestris . Pharm Biol 2000; 38: 112-119
- 8 Esteves I, Souza IR, Rodrigues M, Cardoso LG, Santos LS, Sertiè JA, Perazzo FF, Lima LM, Schneedorf JM, Bastos JK, Carvalho JC. Gastric antiulcer and anti-inflammatory activities of the essential oil from Casearia sylvestris Sw. J Ethnopharmacol 2005; 101: 191-196
- 9 Napolitano DR, Mineo JR, Souza MA, Paula JE, Espindola LS, Espindola FS. Down-modulation of nitric oxide production in murine macrophages treated with crude plant extracts from the Brazilian Cerrado. J Ethnopharmacol 2005; 99: 37-41
- 10 Schoenfelder T, Pich CT, Geremias R, Avila S, Daminelli EN, Pedrosa RC, Bettiol J. Antihyperlipidemic effect of Casearia sylvestris methanolic extract. Fitoterapia 2008; 79: 465-467
- 11 Espindola LS, Vasconcelos Júnior JR, Mesquita ML, Marquié P, Paula JE, Mambu L, Santana JM. Trypanocidal activity of a new diterpene from Casearia sylvestris var. lingua. Planta Med 2004; 70: 1093-1095
- 12 Mesquita ML, Desrivot J, Bories C, Fournet A, Paula JE, Grellier P, Espindola LS. Antileishmanial and trypanocidal activity of Brazilian Cerrado plants. Mem Inst Oswaldo Cruz 2005; 100: 783-787
- 13 Ruppelt BM, Pereira EFR, Gonçalves LC, Pereira NA. Pharmacological screening of plants recommended by folk medicine as anti-snake venom – I. Analgesic and anti-inflammatory activities. Mem Inst Oswaldo Cruz 1991; 86: 203-205
- 14 Borges MH, Soares AM, Rodrigues VM, Andrião-Escarso SH, Diniz H, Hamaguchi A, Quintero A, Lizano S, Gutiérrez JM, Giglio JR, Homsi-Brandeburgo MI. Effects of aqueous extract of Casearia sylvestris (Flacourtiaceae) on actions of snake and bee venoms and on activity of phospholipases A2. Comp Biochem Physiol B Biochem Mol Biol 2000; 127: 21-30
- 15 Raslan DS, Jamal CM, Duarte DS, Borges MH, Lima ME. Anti-PLA2 action test of Casearia sylvestris Sw. Boll Chim Farm 2002; 141: 457-460
- 16 Cavalcante WL, Campos TO, Dal Pai-Silva M, Pereira PS, Oliveira CZ, Soares AM, Gallacci M. Neutralization of snake venom phospholipase A2 toxins by aqueous extract of Casearia sylvestris (Flacourtiaceae) in mouse neuromuscular preparation. J Ethnopharmacol 2007; 112: 490-497
- 17 Itokawa H, Totsuka N, Takeya K, Watanabe K, Obata E. New antitumor principles from Casearia sylvestris Sw. (Flacourtiaceae), structure elucidation of new clerodane diterpenes by 2D NMR spectroscopy. Chem Pharm Bull (Tokyo) 1988; 36: 1585-1588
- 18 Itokawa H, Totsuka N, Morita H, Takeya K, Iitaka Y, Schenkel EP, Motidome M. New antitumor principles, casearins A–F, for Casearia sylvestris Sw. (Flacourtiaceae). Chem Pharm Bull (Tokyo) 1990; 38: 3384-3388
- 19 Itokawa H, Takeya K, Hitotsuyanagi Y, Morita H. Antitumor compounds isolated from higher plants. J Pharm Soc Japan 1999; 119: 529-583
- 20 Santos AG, Ferreira PMP, Júnior GMV, Perez CC, Tininis AG, Silva GH, Bolzani VS, Costa-Lotufo LV, Pessoa CO, Cavalheiro AJ. Casearin X, its degradation product and other clerodane diterpenes from leaves of Casearia sylvestris: evaluation of citotoxicity against normal and tumor human cells. Chem Biodivers 2010; 7: 205-215
- 21 Ferreira PMP, Santos AG, Tininis AG, Costa PM, Cavalheiro AJ, Bolzani VS, Moraes MO, Costa-Lotufo LV, Montenegro RC, Pessoa C. Casearin X exhibits cytotoxic effects in leukemia cells triggered by apoptosis. Chem Biol Interact 2010; 188: 497-504
- 22 Ferreira PMP, Bezerra DP, Silva JN, Costa MP, Ferreira JRO, Alencar NMN, Figueiredo IST, Cavalheiro AJ, Machado CML, Chammas R, Alves APNN, Moraes MO, Pessoa C. Preclinical anticancer effectiveness of a fraction from Casearia sylvestris and its component casearin X: in vivo and ex vivo methods and microscopy examinations. J Ethnopharmacol 2016; 186: 270-279
- 23 Jones CR, Hatley OJD, Ungell A, Hilgendorf SAP, Rostami-Hodjegan A. Gut wall metabolism. Application of pre-clinical models for the prediction of human drug absorption and first-pass elimination. AAPS J 2016; 18: 589-604
- 24 Moreira Da Silva R, Verjee S, Gaitani CM, De Oliveira ARM, Bueno PCP, Cavalheiro AJ, Lopes NP, Butterweck V. Evaluation of the intestinal absorption mechanism of casearin X in caco-2 cells with modified carboxylesterase activity. J Nat Prod 2016; 79: 1084-1090
- 25 Jia L, Liu X. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 2007; 8: 822-829
- 26 Moreira FL, Marques LMM, Lopes NP, De Oliveira ARM. In vitro metabolism studies of natural products are crucial in the early development of medicines. Phytochem Rev 2016; 16: 355-373
- 27 European Medicine Agency. Guideline on bioanalytical method validation. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf Accessed March 28, 2018
- 28 Barr JT, Flora DR, Iwuchukwu OF. Practical Considerations with experimental Design and Interpretation. In: Tweedie DJ, Argikar UA, Nagar S. eds. Enzyme Kinetics in Drug Metabolism, Fundamentals and Applications. Hatfield: Springer Protocols; 2014: 419-429
- 29 Asha S, Vidyavathi M. Role of human liver microsomes in in vitro metabolism of drugs – a review. Appl Biochem Biotechnol 2010; 160: 1699-1722
- 30 Gonzalvo MC, Gil F, Hernández AF, Villanueva E, Pla A. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 1997; 105: 169-179
- 31 Ali B, Kaur S, James EC, Parnar SS. Identification and characterization of hepatic carboxylesterases hydrolyzing hydrocortisone esters. Biochem Pharmacol 1985; 34: 1881-1886
- 32 Tang J, Chambers JE. Detoxication of paraoxon by rat liver homogenate and serum carboxylesterases and A-esterases. J Biochem Mol Toxicol 1999; 13: 261-268
- 33 Laizure C, Herring V, Hu Z, Witbrodt K, Parker RB. The role of human carboxylesterases in drug metabolism: have we overlooked their importance?. Pharmacotherapy 2013; 33: 210-222
- 34 Imai T. Human carboxylesterase isoenzymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 2006; 21: 173-185
- 35 Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 2007; 81: 924-932
- 36 Subramanian M, Tracy T. Methods for Determination of Enzyme Kinetics and metabolic Rates. In: Lyubimov AV. ed. Encyclopedia of Drug Metabolism and Interactions. New York: John Wiley & Sons; 2012: 1-22
- 37 Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58
- 38 Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479
- 39 Kang HE, Lee MG. Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling. Arch Pharm Res 2011; 34: 1779-1788
- 40 Nakamori F, Naritomi Y, Furutani M, Takamura F, Miura H, Murai H, Terashita S, Teramura T. Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats. Drug Metab Pharmacokinet 2011; 26: 465-473
- 41 Beutler JA, Mccall KL, Herbert K, Johnson T, Shoemaker RH, Boyd MR. Cytotoxic clerodane diterpenes esters from Laetia procera . Phytochemistry 2000; 55: 233-236
- 42 Williams RB, Norris A, Miller SJ, Birkinshaw C, Ratovoson F, Andriantsfierana R, Rasamison VE, Kingston DGI. Cytotoxic clerodane diterpenoids and their hydrolysis products from Casearia nigrescena from the rainforest of Madagascar. J Nat Prod 2007; 70: 206-209
- 43 Crow JA, Borazjani A, Potter PM, Ross MK. Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol 2007; 221: 1-12
- 44 Leopold B. Aromatic keto- and hydroxy-polyethers as lignin models III. Acta Chem Scand 1950; 4: 1523-1537
- 45 Marques LMM, Silva-Junior EAS, Gouvea DR, Vessecchi R, Pupo MT, Lopes NP, Kato MJ, De Oliveira ARM. In vitro metabolism of the alkaloid piplartine by rat liver microsomes. J Pharm Biomed Anal 2014; 95: 113-120
- 46 Zhang C, Xu Y, Zhong Q, Li X, Gao P, Feng C, Chu Q, Chen Y, Liu D. In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2. PLoS One 2014; 9: 1-8
- 47 Papadoyannis IN, Gika HG. Peak purity determination with a diode array detector. J Liq Chromatogr Relat Technol 2004; 27: 1083-1092
- 48 Srikanth CH, Chaira T, Sampathi S, Sreekumar VB, Bambal RB. Correlation of in vitro and in vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry. Analyst 2013; 20: 6106-6116